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Abstract
Our bodies are protected from the external environment by mucosal barriers that are lined by 
epithelial cells. The epithelium plays a critical role as a highly dynamic, selective semipermeable 
barrier that separates luminal contents and pathogens from the rest of the body as well as 
controlling the absorption of nutrients, fluid and solutes (1, 2). A series of protein complexes 
including the adherens junction, desmosomes, and tight junctions (TJ) function as the principal 
barrier in paracellular diffusion (3) as well as regulators of intracellular solute, protein and lipid 
transport (4). TJs are composed of a series of proteins called occludins, junctional adhesion 
molecules (JAM), and claudins (5, 6) that reside primarily as the most apical intercellular junction. 
Here we will review one of these protein families, claudins, and their relevance to gastrointestinal 
and liver diseases.
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Introduction
The manner in which the intestines, liver, and pancreas remain intact and functional despite 
the constant exposure to a myriad of luminal contents remains one of the fascinatingly 
complex topics in our field. For children, early life exposures to antigens and microbes may 
dictate immune tolerance or the development of a disease. Increasing awareness of this has 
promoted approaches to modify the barrier with vitamins, probiotics, nutraceuticals as well 
as novel and investigational pharmacological preparations. Hence, understanding the 
structure and function of the mucosal barrier, and in particular, the epithelial barrier is 
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critical. Imagining a 3-dimensional luminal view of the epithelial surface permits a full 
appreciation of the dynamic and complicated manner in which the intercellular netting holds 
the epithelium together. Epithelial cells are the first cellular barrier to the external 
environment that are tightly bound together by a series of cell-cell adhesion complexes. TJs 
are composed of a family of proteins including occludins, junctional adhesion molecules, 
and claudins. The claudin family (from the Latin word for ‘close’) consists of at least 27 
proteins that polymerize to constitute the TJ backbone (7). Due to their dynamic and 
differential expression in cells and organs of the body, the increasing recognition of the role 
of claudins particularly those related to epithelial cells suggests their importance in 
gastrointestinal (GI) and liver health and disease.
Claudins: Expression, regulation, and function in the Gastrointestinal tract
Claudins, encoded by the CLDN genes, are highly conserved 20-27kDa proteins that are 
differentially expressed along the various epithelial compartments of the gastrointestinal 
tract (Table 1). They are composed of four transmembrane proteins including a short 
intracellular NH2-terminal sequence (~1-7 residues), a large first extracellular loop (~52 
residues), a shorter second extracellular loop (16 –33 residues), and a cytoplasmic COOH-
terminal domain that varies considerably in length between different isoforms (21– 63 
residues). These proteins end in an anchoring scaffold-binding PDZ domain (except 
Claudin-12) (8, 9). Given its structure, it is hypothesized that the larger first extracellular 
loop is involved with selective ion permeability, while the shorter second extracellular loop 
may be involved in narrowing of the paracellular cleft and adhesion between the opposing 
cell membranes (10). The topographical distribution and localization of claudins both in 
specific organs and on the epithelial cell is quite varied and summarized in Table 1. For 
instance, in the liver, claudin-1 is expressed at the TJs of hepatocytes and along the lateral 
membrane of bile duct cholangiocytes (11). The diversity of hepatic distribution is 
exemplified by the fact that claudin-2 increases from periportal to pericentral hepatocytes, 
claudin-3 is uniformly expressed, and claudin-5 is restricted to endothelial junctions (12). 
There are also reports of liver expression of claudins -6, -8, -9, and -14 (13). In the pancreas, 
claudins 1-5 and -7 are expressed diffusely (12, 13). In the gallbladder epithelium, claudins 
1-4 (14) and -10 are expressed strongly whereas claudins -7 and 8- are expressed weakly 
(15).
Functionally, specific claudin protein family members regulate barrier or intercellular 
transport of molecules. For instance, claudins -1, -3, -5, -11, -14, -19 regulate epithelial 
barrier whereas claudins -2, -10 and -15, claudins -10 and -17 and claudin -2, selectively 
participate in transport of cations, anions and water respectively.
Claudins are expressed at a baseline during health and can change during states of 
inflammation, disease or cancer. This dynamic regulation can occur at the transcriptional and 
post-translational level (16). Transcription factors including the transcriptional repressor 
SNAI1 may regulate CLDN gene expression (17). Key soluble signaling molecules 
regulating claudin expression include tumor necrosis factor-alpha (TNF-α) and transforming 
growth factor-beta (TGF-β). TNF-α is an important pro-inflammatory molecule involved in 
intestinal inflammation. Exposure of the epithelium to TNF-α can lead to an increase in 
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intestinal TJ permeability in vivo and in vitro (18). NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells) mediates TNF-α-induced changes in claudin-1 and the 
claudin-2 (19). Post-translational modifications of expressed Claudin proteins including 
phosphorylation, SUMOylation, Ubiquitination, and Palmitoylation contribute to altered 
Claudin localization, with implications for barrier function, cellular migration and 
invasiveness (16). The TGF-β family controls numerous cellular functions, including 
proliferation, differentiation and migration in all tissues of the human body (20). In the 
intestines, TGF-β signaling pathways play a crucial role in maintaining intestinal barrier 
function (21, 22), although few have evaluated TGF-β’s influence on claudin expression. In 
endothelial cells, TGF-β activates Activin receptor-like kinase 5 (ALK5), which acts through 
SMAD2/3 to downregulate claudin-5 (23) In colon cancer, loss of SMAD4, which interacts 
with TGF-β and SMAD 2/3 complex, causes an increase in claudin-1 (24). Also, SMAD7 
overexpression in colon adenocarcinoma cells causes increased expression of claudin -1, -4, 
and -7 (25). Altered TJ claudin expression patterns play key roles in numerous pathologies 
including cancers, infections, and diarrheal illnesses; improved understanding of 
mechanisms of regulation could help in designing innovative therapeutic strategies (26).
Claudins in Gastrointestinal Diseases
Inflammatory bowel diseases
Dysregulation of TJ proteins and epithelial permeability leads to increased paracellular 
transport of solutes, water, and other macromolecules that partake in inflammatory signaling 
(27). Changes in claudin expression and localization have been highly associated with 
dysregulated tight junctions in inflammatory bowel diseases (IBD). Functional consequences 
of dysregulated TJ protein expression have been found in endoscopic biopsies from patients 
with mild to moderate Crohn’s disease. Biopsies demonstrate changes at ultrastructural level 
in the subjunctional lateral membrane with decreased TJ strand numbers, increased strand 
discontinuities, and pearl string-like strands, as well as an impaired barrier (28). This 
implicates that the structure of a TJ involving one TJ strand associating laterally with 
another TJ strand of the adjacent cell to form a paired TJ strand is impaired (29). Intestinal 
inflammation in patients with Crohn’s and ulcerative colitis has been associated with the 
upregulation of the paracellular channel claudin-2 in small and large intestine regulated by 
interleukin-13, -6, TNF-α, and interferon gamma (30). The impaired barrier could suggest 
an increase in solute secretion and contribute to diarrhea. Patients with IBD generally 
demonstrate redistribution from the membrane or downregulation of claudin’s -1,- 3, -4, -5, 
-7, and/or -8 in various parts of the intestinal tract (28, 31) providing support for the concept 
of a diminished barrier and enhanced luminal uptake of antigenic macromolecules (32). In a 
recent report, hypoxia-inducible factor-1β drove expression of claudin-1 improving barrier 
function (33). Upregulation of the cation pore- and water-channel forming claudin-2 have 
also been associated with disease progression of inflammatory bowel diseases (28, 31). 
Whether these findings relate to the underlying increased permeability and pathogenesis of 
IBD is yet to be determined.
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Celiac disease is characterized by uptake of gliadin via paracellular endocytosis and 
transcytosis (34). Celiac disease patients are known to have an abnormal TJ structure (35) 
and increased intestinal permeability (36–38). This may lead to dysregulated paracellular 
pathways that could either be a primary factor or secondary finding related to gliadin uptake. 
Similar to IBD, celiac disease is associated with upregulation of cation pore-forming 
claudin-2, downregulation of tightening claudin-4 and -5 channels, and altered localization 
of claudin-4 (39). Other similar studies suggest a similar decrease in claudin-3, while no 
change in claudin-1 or 4 was detected (40). In some cases, the severity of the disease has 
been linked to an even greater increase in claudin -2 and -3 (41). Increased expressions of 
claudins -2 and -3 along with downregulation of claudin-5 suggest structural changes of TJ 
in celiac disease which may contribute to increased permeability observed in celiac disease 
(41).
Gastroesophageal reflux disease
Whether the pathogenesis of GERD and its related symptoms are related to altered barrier 
continues to undergo examination (42). The importance of the barrier in the esophagus is 
emphasized by the fact that the esophageal mucosa is composed of a stratified squamous 
epithelium in contrast to the single layer columnar epithelium of the rest of the GI tract. 
Dilation of the intercellular spaces is a prominent morphological feature of acid-induced 
damage to the stratified squamous epithelium (43). This feature highlights the role of 
claudins in tightening the intercellular spaces since GERD patients have significantly higher 
expression of claudin-1 and -2 (44) and lower expression of claudin -4 compared to healthy 
patients (45). Studies have shown that an early event in the pathogenesis of GERD is an 
acid-induced increase in paracellular permeability in the esophageal epithelium (46). 
However, it is still unknown whether the correlation between claudin expression and 
histopathology of GERD are directly related.
Eosinophilic Esophagitis
The contribution of an altered barrier to the pathogenesis of EoE has been suggested by the 
2-hit theory. If a genetically predisposed host (altered expression/mutations of genes such as 
eotaxin-3, filaggrin, TSLP) develops altered barrier from an exogenous insult (GERD), the 
underlying immunomicromilieu may become activated to promote an eosinophilic response 
(47). Supportive of this is some early histological findings that reveal a reduction of 
claudin-1 protein expression in EoE patients compared to healthy individuals (48) that could 
indicate impairment of the TJ-barrier (49). Spongiosis of esophageal epithelium increases in 
correspondence with reduced claudin-1, that when treated with topical steroids returns to 
normal (50). Along with claudin-1 downregulation, active EoE subjects also showed 
increased epithelial expression of interleukin-9 (IL-9) receptor expression which negatively 
affects E-cadherin expression that might play a significant role in epithelial barrier 
disruption in EoE(51). Claudin-7 expression is attenuated in pediatric subjects with active 
EoE, mediated in part by TGF-β1, resulting in decreased epithelial barrier function (22). 
Though the differential expression of claudins in EoE has not been extensively studied, the 
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impact of claudins on the esophageal epithelial barrier and its regulation of inflammatory 
cytokines contains much potential for therapeutic targets.
Hepatobiliary diseases
Although not directly exposed to ingested luminal proteins, the hepatobiliary tree contains 
an epithelial surface that interfaces luminal products. In this regard, dysregulation of claudin 
expression may contribute to disease pathogenesis. For instance, claudin-3 knock out mice 
tends to develop cholesterol gallstone disease thought to be secondary to increased 
phosphate ion permeability (52). Diminished expression of claudin-1 in cholangiocytes and 
hepatocytes has been shown to be critical to the development of neonatal sclerosing 
cholangitis. The most notable host-pathogen role for a Claudin protein is the crucial role of 
Claudin-1 as a portal of cellular entry for the Hepatitis C virus. Here preclinical studies are 
targeting Claudin-1 directed antibodies as a therapeutic option (Reviewed in (53)).
Conclusion
Claudins are an essential component of TJs in the gastrointestinal epithelial barrier and its 
functional regulation of paracellular transport. As summarized here, altered expression may 
contribute to the development of GI and liver disease or develop as a function of 
inflammation. Claudins also may play roles in infectious diseases, tumorigenesis and 
epithelial-mesenchymal transition in the gut and elsewhere (27, 53). Although no claudin 
specific treatments are available to date, future studies determining the claudin’s expression, 
mediation, and regulation are critical to developing further understanding of the barrier’s 
role in gastrointestinal and liver diseases.
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1. The epithelium and tight junctions are a complex, dynamic organ that protects 
the body from exogenous particles and alters the luminal contents with the 
secreted product.
2. No FDA approved drug directly improves or heals the tight junctions to date.
3. Claudins are one of many proteins that are acting in the tight junction to 
maintain barrier and solute flow.
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Table 1:
Claudin expression in the gastrointestinal tract
Tissue Claudin’s expressed References
Esophagus 1, 4, 7,15 24
Stomach 1, 2, 3, 4, 5, 12, 18, 23 54–59
Small Intestine 1, 2, 3, 4, 5, 7, 8, 12, 15 42, 59–62
Large Intestine 1, 3, 4, 7, 8, 12, 13, 15 59, 60, 63
Liver 1, 2, 3, 5, 6, 8, 9, 14 11–13
Pancreas 1, 5, 7 12, 14
Gallbladder 1, 2, 3, 4 10, 7, 8 15, 16
J Pediatr Gastroenterol Nutr. Author manuscript; available in PMC 2020 May 01.
